WO2013062365A2 - 변이 ctla4 유전자 이입 t 세포 및 이를 포함하는 항암 면역치료용 조성물 - Google Patents
변이 ctla4 유전자 이입 t 세포 및 이를 포함하는 항암 면역치료용 조성물 Download PDFInfo
- Publication number
- WO2013062365A2 WO2013062365A2 PCT/KR2012/008878 KR2012008878W WO2013062365A2 WO 2013062365 A2 WO2013062365 A2 WO 2013062365A2 KR 2012008878 W KR2012008878 W KR 2012008878W WO 2013062365 A2 WO2013062365 A2 WO 2013062365A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cell
- ctla4
- domain
- transformed
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 96
- 239000000203 mixture Substances 0.000 title abstract description 12
- 238000011224 anti-cancer immunotherapy Methods 0.000 title abstract description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 231
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 135
- 210000004027 cell Anatomy 0.000 claims abstract description 117
- 201000011510 cancer Diseases 0.000 claims abstract description 94
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims abstract description 71
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims abstract description 71
- 230000003834 intracellular effect Effects 0.000 claims abstract description 37
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 14
- 230000006044 T cell activation Effects 0.000 claims abstract description 13
- 230000006058 immune tolerance Effects 0.000 claims abstract description 11
- 230000004068 intracellular signaling Effects 0.000 claims abstract description 7
- 230000003213 activating effect Effects 0.000 claims abstract description 6
- 102000018697 Membrane Proteins Human genes 0.000 claims abstract description 5
- 108010052285 Membrane Proteins Proteins 0.000 claims abstract description 5
- 239000000427 antigen Substances 0.000 claims description 51
- 108091007433 antigens Proteins 0.000 claims description 51
- 102000036639 antigens Human genes 0.000 claims description 51
- 108020001507 fusion proteins Proteins 0.000 claims description 43
- 102000037865 fusion proteins Human genes 0.000 claims description 43
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 35
- 108020003175 receptors Proteins 0.000 claims description 21
- 102000005962 receptors Human genes 0.000 claims description 19
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 17
- 241001430294 unidentified retrovirus Species 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 230000003612 virological effect Effects 0.000 claims description 15
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 210000000170 cell membrane Anatomy 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 102000003425 Tyrosinase Human genes 0.000 claims description 5
- 108060008724 Tyrosinase Proteins 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 4
- 241000702421 Dependoparvovirus Species 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 2
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 2
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- MXKCYTKUIDTFLY-ZNNSSXPHSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O[C@H]3[C@H]([C@@H](CO)OC(O)[C@@H]3O)O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O MXKCYTKUIDTFLY-ZNNSSXPHSA-N 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 2
- 102000006815 folate receptor Human genes 0.000 claims description 2
- 108020005243 folate receptor Proteins 0.000 claims description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 2
- 102000000844 Cell Surface Receptors Human genes 0.000 claims 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 1
- 101000654734 Homo sapiens Septin-4 Proteins 0.000 claims 1
- 102100032743 Septin-4 Human genes 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 238000012737 microarray-based gene expression Methods 0.000 claims 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 1
- 101710135378 pH 6 antigen Proteins 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 45
- 230000001093 anti-cancer Effects 0.000 abstract description 26
- 230000004913 activation Effects 0.000 abstract description 14
- 238000002659 cell therapy Methods 0.000 abstract description 13
- 230000019491 signal transduction Effects 0.000 abstract description 9
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 7
- 238000011161 development Methods 0.000 abstract description 7
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 abstract description 4
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 abstract description 4
- 238000001890 transfection Methods 0.000 abstract description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract description 3
- 229940124060 PD-1 antagonist Drugs 0.000 abstract 1
- 230000009897 systematic effect Effects 0.000 abstract 1
- 238000010361 transduction Methods 0.000 abstract 1
- 230000026683 transduction Effects 0.000 abstract 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 70
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 70
- 241000699670 Mus sp. Species 0.000 description 26
- 238000011830 transgenic mouse model Methods 0.000 description 19
- 238000011282 treatment Methods 0.000 description 19
- 241000699660 Mus musculus Species 0.000 description 18
- 230000000259 anti-tumor effect Effects 0.000 description 18
- 230000009466 transformation Effects 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 16
- 230000028327 secretion Effects 0.000 description 16
- 239000003446 ligand Substances 0.000 description 13
- 238000010586 diagram Methods 0.000 description 12
- 238000009169 immunotherapy Methods 0.000 description 12
- 210000004698 lymphocyte Anatomy 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 238000001994 activation Methods 0.000 description 11
- 108060001084 Luciferase Proteins 0.000 description 10
- 239000005089 Luciferase Substances 0.000 description 10
- 108091008874 T cell receptors Proteins 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- 102000000588 Interleukin-2 Human genes 0.000 description 9
- 108010058846 Ovalbumin Proteins 0.000 description 9
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 9
- 230000001177 retroviral effect Effects 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 229940092253 ovalbumin Drugs 0.000 description 8
- 230000004936 stimulating effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 238000002648 combination therapy Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 239000005667 attractant Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000031902 chemoattractant activity Effects 0.000 description 6
- 239000005090 green fluorescent protein Substances 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 210000004970 cd4 cell Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 241000699800 Cricetinae Species 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- -1 gplOO Proteins 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000002271 resection Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000024664 tolerance induction Effects 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001382 Experimental Melanoma Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000003127 anti-melanomic effect Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 3
- 102000008096 B7-H1 Antigen Human genes 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 101001065566 Mus musculus Lymphocyte antigen 6A-2/6E-1 Proteins 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 108010052090 Renilla Luciferases Proteins 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 238000011394 anticancer treatment Methods 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 101150100936 CD28 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 238000003718 Dual-Luciferase Reporter Assay System Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 241001061269 Lestes Species 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001124569 Lycaenidae Species 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 101100222220 Mus musculus Ctla4 gene Proteins 0.000 description 1
- 101001043827 Mus musculus Interleukin-2 Proteins 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005904 anticancer immunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000009172 cell transfer therapy Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- ZXFCRFYULUUSDW-OWXODZSWSA-N chembl2104970 Chemical compound C([C@H]1C2)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2CC(O)=C(C(=O)N)C1=O ZXFCRFYULUUSDW-OWXODZSWSA-N 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 101150045896 ilv-2 gene Proteins 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000008262 pumice Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 102000035025 signaling receptors Human genes 0.000 description 1
- 108091005475 signaling receptors Proteins 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 201000011294 ureter cancer Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464492—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Definitions
- the present invention relates to a genetically modified T ⁇ cells for anti-cancer T-cell therapy and a composition for anti-cancer treatment comprising the same.
- T-cell therapy has shown visible results.
- T ⁇ cell therapy has the basic concept to isolate cancer antigen-specific T cells in the patient's body and to multiply them through in vitro cell culture and return them to the patient's blood to attack seed cancer cells. (Nat. Rev. Immunol., Vol. 6, pp 383). In other words, a small number of cancer-specific T-cells are amplified in vitro and used for treatment.
- the antigen specificity and tissue penetrating power of T lymphocytes are expected to effectively remove cancer foci scattered in various places at once, and T-cells are directly exposed through extravasation. As it can infiltrate tissues and specifically kill antigen-expressing cells, it has the advantage of removing cancer cells by infiltrating several metastatic tissues respectively. Recently, the development of cell therapy using these anti-cancer T-cells has become more active. It is a situation.
- LAK LAKUymphokine-activated killer
- TIL tumor-infiltrating lymphocyte
- Lymphocyte depletion prior to T-cell injection creates room for the next T-cell to proliferate, while regulating T-cells, a limiting factor for T-cell activation. It is estimated to have the effect of eliminating it. This response rate is the highest response ever to immunotherapeutics ever attempted, giving very encouraging predictions about its potential.
- T-cell therapies Thanks to the success of cancer antigen-specific T-cell therapies, recent trends in T-cell therapies have led to genetic manipulation of isolated T-cells. Research into genetically engineered T cell therapy in patients is being actively conducted. Genetic T Cell Therapy After multiplying cancer antigen-specific T cells isolated from the cells, T-cells were transformed using a retrovirus for specific gene expression and re-injected into the patient. In many cases, clinical trials are already underway.
- cancer antigen-specific T cells from the blood of patients with melanoma secrete IFN- ⁇ when stimulated with the cancer antigen Melan-A peptide
- cancer antigen-specific T cells from cancer tissues or lymph nodes of cancer tissues has been reported to be inactivated, stimulating with cancer antigens, but not secreting IFN-Y.
- T-cells in the peripheral blood of cancer patients that can recognize and respond to cancer cells, but when these T-cells enter cancer tissues, they are locally inactivated, i.e. tolerated.
- T-cell tolerance caused by cancer cells is identified, and the functions of the cells are removed, their functions are eliminated or inhibited, antagonists or antibodies to the receptors, etc.
- Representative receptors known to be involved in T-cell tolerance are CTLA4 (Cytotoxic Ttoxic Lymphocyte ⁇ Associated Protein 4, or T ⁇ Lymphocyte Antigen 4), also called CD152.
- CTLA4 is a superfamily of immunoglobulins (i ⁇ unoglobulin) that is expressed on the surface of T ⁇ cells and transmits an inhibitory signal to T-cells. Tolerance induction through T-cell inactivation of CTLA4 protein was confirmed by the observation of severe lymphoproliferative disease and autoimmune disease in CTLA4 knockout mice.
- CTLA4 has a sequence similar to that of CD28, a T ⁇ cell cost imulatory protein, and competitively binds to CD28 against CD80 and CD86, also called B7 in antigen-presenting cells.
- CTLA4 carries an inhibitory signal and CD28 delivers a stimulatory signal. That is, the binding of B7 and CTLA4 inhibits the activation of T-cells, and the binding of B7 and CD28 induces T-cell activation.
- PD1 is expressed on the T-cell surface; PE ) is known to inhibit T-cell activation by binding to -L1.
- PD-L1 is a family member having a structure similar to that of CD28, and is mainly expressed on the surface of immune cells such as T-cells, B-cells, macrophages, and c ⁇ ndritic cells. It is also known to be expressed in some non-lymphoid cells such as cardiovascular endothelial cells.
- T3 ⁇ 4 ⁇ ng ntibody has been reported to increase anti-cancer immunity (Proc. Natl. Acad. Sci., 17; 99 (19): 12293-7), PI) ⁇ L1 immunosuppressive action on the surface of cancer cells of Evidence is being reported one after another.
- Ipilimumab an anti-CTLA4 antibody developed by BMS (Bristol-Myers Squibb), has been shown to be clinically effective in suppressing anticancer immunotolerance and showing antitumor effect against metastatic melanoma.
- BMS Stel-Myers Squibb
- CTLA4 or anti-PD1 antibodies when used, systemic inhibition of CTLA4 or PI) 1 results in systemic inhibition of T-cell tolerance to autoantigens as well as anticancer T-cells. It is known to cause fatal side effects of autoimmune diseases.
- the present inventors genetically engineered anticancer T ⁇ cells to express CTLA4 decoy receptor, a CTLA4 mutant from which the intracellular inhibitory signaling domain of CTLA4 has been removed.
- CTLA4 decoy receptor a CTLA4 mutant from which the intracellular inhibitory signaling domain of CTLA4 has been removed.
- the inhibition of T ⁇ cell tolerance by cancer cells can be solved to some extent because the inhibitory signal is not transmitted to the cells even when the CLTA4 inducing receptor binds to the ligand B7.
- Competitive inhibition of the binding of B7, a ligand, with CD28 which still induces T ⁇ cell activation, resulting in T- ⁇ _ ⁇ Zt ⁇ hindering.
- the present inventors genetically engineered the CTLA4-CD28 chimeric protein by removing the intracellular inhibitory signal transduction domain of CTLA4 and integrating the intracellular stimulatory signaling domain of CD28 protein in place.
- Designed anti-cancer T-cells see FIG. 1, when ligand is bound to CTLA4, T is induced by binding of CTLA4 to ligand by the action of intracellular activation signal transduction domain of CD28 contained in CTLA4-CD28 chimeric protein.
- -It has the effect of converting the cell activity suppression signal into a stimulatory signal, which not only overcomes T ⁇ cell tolerance by cancer cells, but also improves anticancer ability through T-cell activation.
- the object of the present invention is to remove the intracellular signaling domain of the T-cell immune tolerance receptor, and to fuse the intracellular signaling domain of the T-cell activating surface protein CD28 to the fusion protein and It provides a gene that encodes this.
- Still another object of the present invention is to provide a cancer antigen-specific transformed T-cell transformed with a virus or a non-viral carrier comprising the gene and a method for producing the same.
- Another object of the present invention to provide a pharmaceutical composition for treating cancer comprising the transformed T-cells.
- Still another object of the present invention is to provide a method for treating cancer, comprising administering a pharmaceutically effective amount of the transformed T-cells to a subject with cancer disease.
- Still another object of the present invention is to provide a use of the transformed T-cells for the manufacture of a pharmaceutical composition for treating cancer diseases.
- CTLA4 CD28 chimeric protein or PD1-CD28 chimeric protein, and genes encoding the same.
- the present invention is a viral or non-viral carrier comprising the gene
- the present invention provides a manufacturing method.
- the present invention provides a pharmaceutical composition for treating cancer comprising the transformed T-cell of the present invention.
- the present invention also provides a method for treating cancer, comprising administering a pharmaceutically effective amount of the transformed T-cells to a subject having a cancer disease.
- the present invention provides a use of the transformed T-cell in the manufacture of a pharmaceutical composition for treating cancer diseases.
- T-cells incorporating the CTLA4-CD28 chimeric gene or PD1-CD28 chimeric gene according to the present invention not only solve the problem of inhibiting the therapeutic effect due to immunotolerance of cancer cells, but rather the signal transduction of CD28.
- activating the T-cell has the advantage of maximizing the anticancer effect by inducing the activation,
- CTLA4 or PI) 1 specifically in cancer cells, the development of autoimmune diseases due to systemic T-cell activation caused by the use of nonspecific CTLA4 or PD1 antagonists such as anti-CTLA4 antibodies. Side effects can be minimized.
- the anticancer pharmaceutical composition comprising T-cells incorporating the CTLA4-CD28 chimeric gene or PD1-CD28 chimeric gene according to the present invention has T ⁇ cell immunotherapy having remarkably superior cancer treatment efficacy compared to conventional methods. It can be usefully used.
- FIG. 1 is a diagram showing the principle of cancer treatment of cancer antigen specific T-cells expressing CTLA4-CD28 chimeric protein:
- CTdc CLLA4 attractant receptor
- CTC28 CTLA4-CD28 chimeric protein.
- Figure 2 shows the gene construct and plasmid cleavage map for the expression of CTLA4 ⁇ CD28 It is a figure which shows.
- CTLA4 EC extracellular domain of CTLA4
- CD28 CP the intracellular domain of CD28
- CTLA4 empty retroviral vector without CD28.
- Figure 3 is a diagram showing the cell division capacity and IFN-Y secretion capacity of T-cells transformed with the CLTA4-CD28 chimeric gene.
- FIG. 4 is a diagram showing the secretion capacity of IFN ⁇ ⁇ , cancer cell killing ability and tumor treatment effect of CD8 T-cells transformed with CLTA4—CD28 chimeric gene.
- FIG. 5 is a diagram showing antigen response when cell culture of T cells transformed with CLTA4 ′ CD28 chimeric gene.
- Figure 6 is a diagram showing the combination of the engineered CD4 and CD8 T-cell combination therapy.
- Figure 7 shows the effect of 0T-II ⁇ : ⁇ ⁇ 3 ⁇ 43 ⁇ 4 ⁇ for E.G7 tumors.
- Figure 8 shows the 0T—IT cells and CTLA4-CD28 chimeric genes for E.G7 tumors.
- Figure 1 shows the effect of the combined administration of 0T—II T—cells transformed into. (A: No processing, ⁇ : 0T-1 only, : T-1 + 0T-II, ⁇ : 0T-1 + OT-II CTC28)
- FIG. 9 is a diagram showing the effect of tumor treatment by the simultaneous transformation of 0T-II and OT-1 ⁇ -cells.
- Figure 10 shows the anti-melanoma effect of GM CD4 and CD8 T-cell combination therapy.
- Figure 11 shows Akt phosphorylation of T-cells transformed with CTLA4-CD28 chimeric gene.
- FIG. 12 is a diagram showing the results of analyzing a T-cell transformed using the gene constructs for CTLA4-CD28 expression using a flow cytometry.
- Fig. 13 shows the secretion ability of IFN- ⁇ when each receptor of T-cells transformed with CTLA4-CD28 chimeric gene is stimulated.
- Figure 14 shows the effect of OT-I T-cell administration alone on E.G7 tumors.
- 15 is a diagram showing the number and antigenic reactivity of these T-cells in mouse spleen after administration of transformed 0T-I and OT-II T-cells to mice with E.G7 tumors.
- FIG. 16 is a diagram showing the proliferation of genetically engineered T ' cells in the blood of melanoma efficacies of GM CD4 and CD8 T' cell combination therapy.
- Figure 17 shows the effect on anti-melanoma of the engineered CD4 and CD8 T-cell combination therapy.
- FIG. 18 is a diagram showing the effect of ILV2 on anti-melanoma of GM CD4 and CD8 T-cell combination therapy.
- extracellular domain is protruded out of the cell to bind the ligand and the like .
- Transmembrane domain refers to a domain located in the cell membrane in CTLA4, CD28, etc.
- Intracellular domain refers to a domain located inside a cell and intracellularly delivering a signal transmitted by binding an extracellular domain and a ligand. The intracellular domain may be classified into an inhibitory signaling domain or an activat ion signaling domain according to the nature of the signal.
- anticancer includes “prophylaxis” and “treatment”, where “prevention” means cancer antigen specific T- transformed with CTLA4-CD28 chimeric gene or TO1-CD28 chimeric gene according to the present invention. Means any action in which cancer is inhibited or delayed by administration of a composition comprising cells, wherein “treatment” refers to a cancer antigen specific T transformed with the CTLA4-CD28 chimeric gene or PD1 ⁇ CD28 chimeric gene according to the present invention.
- the present invention provides an intracellular signaling domain of a T-cell surface immune tolerance inducing receptor. Remove and provide a fusion protein that fuses the intracellular signaling domain of the T-cell activating surface protein CD28.
- the T-cell surface tolerance induction receptor and CD28, a T ⁇ cell activating surface protein are preferably fused by the T-cell surface tolerance induction receptor or the transmembrane domain of CD28, but are not limited thereto.
- the T-cell surface tolerance induction receptor is preferably CTLA4 (Cytotoxic T lymphocyteassociated antigen4) or PE) 1.
- the fusion protein is preferably composed of an extracellular domain of CTLA4 ⁇ a transmembrane domain of CTLA4-an intracellular domain of CD28 or an extracellular domain of CTLA4-a transmembrane domain of CD28 ⁇ a CD28 intracellular domain.
- the fusion protein is a cell in the extracellular domain of PE ) 1 -PI) 1 _domain rCD28 ⁇ 'i_domain or the extracellular domain of PD-1-transmembrane domain of CD28 -CD28 It is preferable that the domain is configured, but is not limited thereto.
- the CTLA4 preferably has an amino acid sequence of human-derived SEQ ID NO: 1 or a mouse-derived SEQ ID NO: 2.
- amino acid sequence of 1 to 161 is a site that binds to an extracellular domain, that is, a ligand such as B7, and the amino acid sequence of 162 to 189 is a transmembrane domain,
- the amino acid sequences from 190 to 223 represent intracellular domains.
- the CD28 preferably has an amino acid sequence of human-derived SEQ ID NO: 3 or a mouse-derived SEQ ID NO: 4.
- amino acid sequence of 1 to 152 is a site that binds to an extracellular domain, that is, a ligand such as B7
- amino acid sequence of 153 to 178 is a transmembrane domain, 179 to 220.
- Amino acid sequence up to and including the intracellular domain, amino acid sequence of amino acid sequence 1 to 150 in the amino acid sequence of SEQ ID NO: 4 is the site that binds to the extracellular domain, that is, ligands such as B7, amino acids from 151 to 176
- the sequence is the transmembrane domain, amino acid sequences 177-218 represent intracellular domains.
- CTLA4 when used for the CLTA4 'CD28 chimeric protein, a portion of the CTLA4 intracellular domain is additionally added to the extracellular domain and the transmembrane domain of CTLA4 within the range where no intracellular inhibition signal of CTLA4 is transmitted. It will be apparent to those skilled in the art that the sequence is further included, or that the CD28 transmembrane domain further contains some sequence of the CD28 transmembrane domain, which is included in the scope of the present invention.
- CTLA4-CD28 chimera When the transmembrane domain of CD28 is used in a protein, a portion of the extracellular domain of CD28 is further included in the intracellular and transmembrane domains of CD28 within a range that does not affect CTLA4 and ligand binding, or It is also common that the extracellular domain further includes some sequences of the CTLA4 transmembrane domain, which are included in the scope of the present invention. It is obvious to the technician.
- CTLM-CD 28 chimeric protein source provided in the present invention has an amino acid sequence of any one of the example sequence L. No. 5 ′ .
- the extracellular domain of CTLA4, the transmembrane domain of CTLA4, and the intracellular domain of CD28 are sequenced.
- the amino acid sequence of No. 5 or the amino acid sequence of SEQ ID NO: 6 is not limited thereto.
- the extracellular domain of CTLA4 cell membrane domain of CD28
- the intracellular domain of CD28 preferably has an amino acid sequence of SEQ ID NO: 7, but is not limited thereto.
- the extracellular domain of PD1-transmembrane domain of PD1-intracellular domain of CD28 or extracellular domain of PE L-transmembrane domain of CD28-intracellular domain of CD28 preferably have an amino acid sequence of SEQ ID NO: 8 It is not limited.
- the present invention is a pore-t gene encoding the fusion protein of the present invention.
- the cell domain of CTLA4-transmembrane domain of CTLA4 is preferably the nucleo sequence of SEQ ID NO: 9
- the CD28 cell domain is the nucleotide of SEQ ID NO: 10 It is preferably an id sequence, but is not limited thereto.
- the present invention also provides a virus or non-viral carrier comprising a gene encoding the fusion protein of the present invention.
- the viral or non-viral carrier can be used without limitation as long as it can transform animal cells, especially T-cells, etc. by infection.
- the virus is preferably a retrovirus, a lent ivirus, an adenovirus and an adeno-associated virus, preferably a retrovirus, a lentiviral and an adeno-associated virus.
- a retrovirus preferably a retrovirus, a lentiviral and an adeno-associated virus.
- the non-viral carrier is preferably one using a transposon system (Hackett et al., US 6,489,458) and the like, but is not limited thereto. It will be apparent to one skilled in the art that any match can be used.
- the present invention also provides a T-cell transformed using a virus or non-viral carrier comprising a gene encoding a fusion protein of the present invention.
- the T-cells are T-cells transfected with a cancer antigen specific T-cell or a CARCChimeric Antigen Receptor gene, which is a chimeric antigen receptor, and a cancer antigen-specific CD4 T-cell (Helper T—cell, helper T-cell). ) Or CD8 T-cells (cytotoxic T-cells).
- the chimeric antigen receptor is a cell membrane or intracellular signal of T-cell activating proteins (CD3-zeta chain, CD28, 41BBL, 0x40, I COS, high-affinity receptor for IgE (FcsRI) and other T-cell activating proteins)
- T-cell activating proteins CD3-zeta chain, CD28, 41BBL, 0x40, I COS, high-affinity receptor for IgE (FcsRI) and other T-cell activating proteins
- the term "transplantation site” refers to a protein in which the delivery site is fused with a single chain Fv fragment of a cancer antigen-specific antibody.
- T-cells specific for the cancer antigen are cultured in vitro with T-cells (tumor infiltrating lymphocytes) isolated from cancer tissues of the patient .
- Viruses such as retroviruses are cloned after cloning genes that are known to be known as ' recognized ' receptors, ie, cancer antigen-specific T-cell receptor (TCR) genes.
- T cell (Science. 2006; 314 (5796): 126-9), extracellular domain of T-cell receptor (TCR)
- CAR Chimeric Antigen Receptor
- CAR Transduced CAR ⁇ transfected T ⁇ cells
- 116 (7): 1035-1044 may be used, but is not limited thereto.
- the antigen that can be specifically recognized by cancer antigen-specific T cells are cancer antigen-specific T cells.
- MAGE, WT-1, etc. may be exemplified, but is not limited thereto, and is specific to other cancers.
- T-cells according to the present invention so long as the antigens expressed by the present invention also meet the object of the present invention.
- the present invention removes the intracellular inhibitory signal transduction domain of CTLA4 and replaces
- An anticancer T-cell engineered to express white matter was designed and loaded into CTLA4.
- CTLA4-CD28 chimeric gene or PD1-CD28 chimeric according to the present invention
- Anti-cancer treatment ⁇ pharmaceutical composition comprising transgenic T-cells . _silver. It can be useful for T cell-cell immunotherapy, which has remarkably superior cancer efficacy compared to conventional methods.
- the present invention also provides a pharmaceutical composition for treating cancer comprising the transformed T-cells of the present invention.
- the cancer pharmaceutical composition may comprise a cancer antigen specific CD4 T-cell or CD8 T-cell transformed with CTLA4-CD28 chimeric gene or PD1-CD28 gene, CTLA4—CD28 chimeric gene or PD1— More preferably, it includes both cancer antigen specific CD4 T—cells and CD8 T-cells transformed with the CD28 gene.
- the cancer or carcinoma is not particularly limited and includes solid cancer and hematological cancer.
- gastric cancer Preferably gastric cancer, lung cancer, breast cancer, ovarian cancer, liver cancer, bronchial cancer, nasopharyngeal cancer, laryngeal cancer, pancreatic cancer, bladder cancer, colon cancer, colon cancer, pancreatic cancer, cervical cancer, brain cancer, prostate cancer, bone cancer, skin cancer, thyroid cancer, parathyroid cancer, Renal cancer, esophageal cancer, biliary cancer, testicular cancer, rectal cancer, head and neck cancer, cervical cancer, ureter cancer, osteosarcoma, neuroblastoma, myeloma, fibrosarcoma, rhabdomyosarcoma, astrocytoma, neuroblastoma or glioma, etc.
- compositions according to the present invention may further comprise a pharmaceutically acceptable carrier.
- a pharmaceutically acceptable carrier for oral administration, binders, suspending agents, disintegrating agents, excipients, solubilizers, dispersants, stabilizing agents, suspending agents, pigments, flavorings, and the like may be used.
- Isotonic and stabilizing agents can be used in combination, and for topical administration, bases, excipients, lubricants, preservatives and the like can be used.
- Formulations of the pharmaceutical compositions of the present invention can be prepared in various ways in combination with the pharmaceutically acceptable carriers described above.
- the anticancer composition may typically include a surfactant that facilitates movement across the membrane.
- surfactants include the steroid-standing _ .. ⁇ 3 ⁇ 4 0 lZii ⁇ U (I, -3 ⁇ dieul LES oil) propyl - ⁇ , ⁇ , ⁇ - chloride (D0TMA) cationic lipids, or such call Leste And various compounds such as hemisuccinate and phosphatidyl glycerol.
- the present invention administers to a subject a composition comprising a cancer antigen-specific T cells transformed with the CTLA4 ′ CD28 chimeric gene or PD1-CD28 chimeric gene according to the present invention to treat cancer and inhibit cancer growth.
- a composition comprising a cancer antigen-specific T cells transformed with the CTLA4 ′ CD28 chimeric gene or PD1-CD28 chimeric gene according to the present invention to treat cancer and inhibit cancer growth.
- composition according to the invention can be administered in a pharmaceutically effective amount to treat cancer cells or their metastases, or to inhibit the growth of cancer. It may vary depending on various factors such as cancer type, age of the patient, the nature and extent of symptoms, the type of current treatment, the number of treatments, the dosage form and the route, and can be easily determined by a person skilled in the art.
- the composition according to the present invention may be administered together or sequentially administered with the pharmacological or physiological components described above, and may also be administered in combination with additional conventional therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. . Such administration may be single or multiple administration.
- Pmel-1, ⁇ - ⁇ , B6 and Thyl.l + congenic B6 mice were obtained from Jackson Lab.
- 0T-II mice with RAGF 7 ' background were obtained from Taconic. All transgenic mice have a B6 background. Mice were reared in a facility free of specific pathogens within the National Cancer Center and followed the guidelines of the National Center for Laboratory Animal Care and Use.
- E.G7 lymphoma cells and B16-F10 (B16) melanoma cells were from B6 mice.
- Phoenix E.co® and Pheonix GP cell lines were obtained from ATCC under the permission of Dr. Garry Nolan (Standford University) (ATCC No. SD3444 and SD3514).
- CD8 T cells or CD4 + CD25— cells were positively selected using anti-CD8 microbeads (inicrobeads), or CD4 + CD25-regulated T-cell separation kit (Myltenyi). Biotec) was used for negative selection (negative selection).
- Nucleotide sequences encoding the extracellular and transmembrane domains of mouse-derived CTLA4 (SEQ ID NO: 9) and the nucleotide sequences encoding the intracellular domain of mouse CD28 (SEQ ID NO: 10) for the production of CTLA4-CD28 chimeras were determined by mouse CTLA4 and It was obtained by amplification by polymerase chain reaction (PCR) from the fulllasmid containing CD28 cDNA.
- the two amplified fragments were combined by blunt end ligation and cloned into a cloning vector.
- the cDNA of the CTLA4-CD28 chimeric gene was then cloned into pMIG-w retroviral vector (see FIG. 2 (a)) obtained from Dr. Yosef Refaeli of the National Jewish Medical and Research Center.
- CTLA4 attractant receptor was amplified by PCR using nucleotide sequences encoding the extracellular and transmembrane domains of CTLA4 according to SEQ ID NO: 9 and cloned into pMIG-w retroviral vector (see FIG. 2 (b)). .
- Jurkat T-cells (1 ⁇ 10 7 ) are retroviral expression plasmids, RE / AP luciferase fulllasmid (provided by Professor Arthur Weiss of the University of California) and pRL-TK Renilla luciferase for standardization was combined with plasmid (Promega).
- transformation was performed using electroporation at 0.4-cnrgap using Gene Pulser of Bio-Rad Laboratories at 250 V and 950 uF.
- Luciferase activity was measured using a luminometer (luminometer, Promega, Promega) using a dual-luciferase reporter assay system. The activity of Drosophila luciferase was normalized using Renilla luciferase activity.
- Jurkat T-cells were transformed according to the above protocol using only retrovirus plasmids except luciferase plasmids.
- the transformed cells were treated for 10 minutes on ice using either mouse anti-human CD28 antibody or normal hamster IgG or hamster anti-mouse CTLA4 antibody (2 yg / ml). This was followed by crossl inking with goat anti-mouse IgG or anti-hamster IgG (5 yg / ml) for 10 minutes on ice.
- the plasmid pMD.G which encodes a retroviral plasmid and VSV-G cDNA, was transformed into a Phoenix GP cell line using Lipofectamine 2000 (Invitrogen). (transfection). After 48 hours, the supernatant containing VSV G pseudotyped retrovirus was recovered. Phoenix Eco cell line was transformed overnight using supernatant containing retrovirus.
- GFP-positive Phoenix Eco cell lines were developed to produce stable producers for producing ecotropic retroviruses. sorter) (FACS Aria, BD Biosciences).
- the supernatant containing ecotropic retrovirus was recovered and concentrated 10-fold using a centrifugal filter device (Ami con Ulra-15, cutoff value 100 kDa, Millipore, Millipore).
- Splenocytes from normal or transformed mice were transformed into anti-CD3s (5 ug / ml, 145-2C11) and anti-CD28 (2 ug / ml, bound to the plate for transformation of T-cells with retroviruses. 37.51) Stimulated using antibodies or antigenic peptides.
- T-cells were centrifuged at 2500 rpm for 90 minutes using concentrated retroviruses. (Spin infection). This process was repeated one more day.
- spin infection 6 iig / ml of polybrene (Sigma, Sigma) was added to the culture supernatant, or retrospectin-coated plates ((15 ⁇ g / ml, Takara)
- polybrene Sigma, Sigma
- retrospectin-coated plates ((15 ⁇ g / ml, Takara)
- the procedure was performed 48 hours after stimulation, transformed T-cells were fresh containing 30 unit / nil mouse IL-2 (Invitrogen). Transferred to fresh medium and left for 48-72 hours before pumice.
- GFP-positive cells (2x10 4 / wel U) isolated by cell-sorting were treated at various concentrations in the presence of irradiated splenocytes (2x 10 5 / wel 1) for 48 hours. Stimulated using CD3 antibody or antigen peptide.
- Cytokines in supernatants were measured using ELISA Sets from BD Biosciences.
- transformed Pniel-l T-cells were stimulated with 1 ⁇ hgplOO peptide in the presence of spleen cells for 48 hours and then various activated T-cells were detected. After co-culture with B16 cells (1 ⁇ 10 4 ) for 20 hours, the cells were washed with PBS. The remaining B16 cells were washed for 6 hours at 3 ⁇ 4 thymidine for recovery and radioactivity of cells. ) was pulsed.
- Transformation using T-cell (Adoptive T-cell transfer)
- mice were injected subcutaneously at day 0 with either E.G7 cells (1-2 ⁇ 10 6 ) or B16 cells (1 ⁇ 10 5 ). T-cells transformed with retroviruses were introduced into mice on day 7. In the B16 melanoma model, on the day T-cells were introduced, mice were subjected to lymphocyte depletion by nonmyeloablative total body irradiation (TBI) (4 Gy).
- TBI nonmyeloablative total body irradiation
- Tumor growth was measured at intervals of 3-4 days using a caliper, and the approximate size was calculated as follows: length X width G ⁇ X ⁇ .
- mice were euthanized when tumors exceeded 500 ⁇ 2 .
- extracellular extracellular (ex vivo)
- the T- cells were fixed and the tube cylinder (fixed and permeabi 1 i zed) (BD cytof ix / cytoperm kit) active on dwin i Then, stained with PE_labeled anti-mouse IL-2 or IFN-Y.
- CTLA4 mutant and CTLA4 decoy receptor and CTLA4-CD28 chimeric protein (SEQ ID NO: 2), in which the intracellular inhibitory signaling domain of mouse-derived CTLA4 (see SEQ ID NO: 2) has been removed
- a retroviral construct expressing 6) was constructed as disclosed in FIG. 2 (b).
- EV refers to pMIG-w, a retroviral vector in which nothing is inserted, and cDNA of CTLA4—CD28 chimera (CTC28) gene and CTLA4 attractant receptor (CTdc) is the IRES-GFP (green fluorescent protein) of pMIG-w. ) Is inserted in front of the cassette.
- CTC28 CD28 chimera
- CTdc CTLA4 attractant receptor
- Jurkat T-cells were treated with an empty plasmid containing no CLTA4 attractor or CTLA4T £ D.28-Mera gene, and a RE / AP luciferase plasmid containing a CD28 response element. After transformation, anti-CD3 and anti-CD28 antibodies When stimulated with anti-CD3 antibody as previously reported. It was confirmed that luciferase activity is significantly increased compared to the case of stimulating alone (see FIG. 3 (a)). This demonstrates that signaling by endogenous CD28 is well occurring.
- Akt phosphorylation was not increased in the Jurkat cell line transformed with the CTLA4 attractant gene, whereas Akt phosphorylation was performed after the CTLA4—CD28 chimera was transformed into the Jurkat cell line and stimulated with an anti-CTLA4 antibody. Phosphorylation was confirmed to increase (see FIG. 11).
- the spleen cells were transformed with an empty plasmid containing no CTLA4-CD28 chimeric gene and a plasmid having a GFP reporter gene containing a CD28 response element, followed by anti-CD28 and anti-CTLA4.
- stained with antibodies and ⁇ u GE £ - i-positive cells for analysis using flow cytometry sorter CTLA4-CD28 chimeric expression levels were identified that were higher than endogenous CTLA4 expression levels (see Figure 12).
- CTLA4-CD28 chimeric expression levels were identified that were higher than endogenous CTLA4 expression levels (see Figure 12).
- the transformed spleen T-cells were stimulated with anti-CD3, anti-CD28 and anti-CTLA4 antibodies, overexpression of CTLA4-CD28 reduced the IFN- ⁇ inhibitory ability of the anti-CTLA4 antibody. Confirmed. (See Figure 13).
- CTLA4—CD28 chimeric protein does not transmit an inhibitory signal when the ligand binds to the extracellular domain of CTLA4, as well as the CD28 intracellular domain of CTLA4-CD28 chimeric protein. It has been shown that T-cell activation is markedly increased by delivering stimulatory signals intracellularly.
- an antigen-specific TCR trait called i1 ⁇ 2el-l CD8 T-cells (Pmel-1 T-cells) derived from converting mice were transformed using retroviruses containing the CTLA4-CD28 chimeric gene.
- Pmel-1 T-cells specifically recognize gplOO, a tumor antigen expressed on the surface of syngenic B16 melanoma cells.
- the transformed Pmel-1 T-cells showed higher IFN- ⁇ secretion ability than the control (see Fig. 4 (a)), but cytolytic activity on in-vitro against B16 cells. ) Showed no significant improvement (see Figure 4 (b)).
- Pniel-l T-cells transformed with CTLA4—CD28 chimeric gene showed significant anti-tumor effect when transplanted into lymphocyte-depleted B16 tumor-bearing mice, even when co-treated with high doses of IL-2. It can be confirmed that (see Fig. 4 (c)).
- Pmel-1 T-1 cells transformed with the CTLA4-CD28 chimeric gene did not show a significant improvement in its function.
- an anti-OVA TCR transgenic mouse designed to express TCRs that specifically recognize ovalbumin (OVA) in T ⁇ cells was introduced. It was.
- T cell activation by the OVA antigen was confirmed by the secretion ability of IL2 and IFN-Y.
- 0T-I and 0T-II T-cells were transformed with retroviruses containing the CTLA4-CD28 chimeric gene and then measured for cytokine production. Stimulated with OVA in the presence of antigen presenting cells (APC).
- 0T-1 CTC28 or 0T-II CTC28 means 0T ⁇ 1 T-cell or 0T-II T-cell transformed using CTLA4-CD28 chimeric gene.
- CD4 ⁇ -cells are known to have anti-tumor traces of CD8 ⁇ -cells and are known as ⁇ F ⁇ r ⁇ ⁇ ⁇ r3 ⁇ 4T Reinforced CD4 anti-tumor antitumor-specific CD8 T-cells
- the tumor effect could be doubled.
- the present inventors have investigated whether CD4 T-cells transformed using the CTLA4-CD28 chimeric gene can increase the anticancer efficacy of CD8 T-cells by using 0T-I and O-Tl cells according to Experiment 3 Tested. For this, OVA was selected as a model tumor antigen, and a syngeneic EL4 lymphoma cell line (E.G7) transformed with OVA cDNA was selected as a tumor model (see FIG. 6).
- the results presented in FIGS. 7 and 8 represent at least two independent experimental results.
- CTLA4-CD28 chimeric gene increased the antigenic reactivity of CD8 T-cells, although it was less effective than CD4 T-cells.
- CTLA4 and CD28 chimeric genes were used to transform both 0T—II T-cells and 0T-I T-cells to determine whether they could be transformed.
- transfection with the CTLA4-CD28 chimeric gene when injected into mice with E.G7 tumors (see FIG. 6), only 0 ⁇ - ⁇ Compared with the case of transformation, it showed a much stronger anti-tumor effect.
- mice with E.G7 tumors were isolated from mice injected with gene-transformed 0T-I and 0T ⁇ II T-cells. And Tov cells were stimulated in vitro with an ovalbumin (0VA) peptide. Genetically transformed 0T-II T-cells had a much higher percentage of IL-2 and IFN ⁇ ⁇ -producing cells than control 0T ⁇ II T-cells when analyzed by intracellular cytokine staining in cells ( See FIG. 15 (a)). In addition, the total number of gene transformed 0T—II T-cells was increased compared to control 0 ⁇ - ⁇ T—cells (see FIG. 15 (b)).
- the present invention isolated ovalbumin peptides in vitro after isolating whole CD8 T ⁇ cells and transforming 0T-IT-cells transformed with the same number of genetically-transformed 0T-I and empty vectors. And incubated with antigen presenting cells (APCs).
- the present invention measured IFN-y secretion by ELISA.
- transgenic 0T—I T-cells produced a greater amount of IFN-Y than 0T-I T-cells transformed with empty vectors (see FIG. 15 (c)).
- the genetically transformed 0T-I and 0T-II T-cells retained their increased activity even after administration to mice with tumors.
- Model for Experimental Example 4 the model containing the actual tumor antigen using 0VA called artificial tumor antigen for the test because the anti-tumor effect, CTLA4 eu CD28 transformed with the chimeric gene and the CD4 T-eu CD ⁇ yo cells It is necessary to test the antitumor effect in B16 melanoma is one suitable model tumor because it has an endogenous gplOO antigen specifically recognized by Pme ⁇ 1 CD8 T ⁇ cells.
- B16 tumors have poor immunogenicity (i ⁇ nugenecity) and are known to be resistant to T-cell immunotherapy, and Pmel-l T-cells transformed with CTLA4-CD28 chimeric gene in the present invention.
- the antitumor effect was not significantly improved (see Experimental Example 2), it was reported that T-cell immunotherapy using Pmel-1 T ⁇ cells could be effective by adding polyclonal CD4 T-cells. have.
- Pmel-l T-cells which are CD8 T-cells, were brewed and observed for decreasing tumor volume.
- polyclonal CD4 T cells (regulatory T—CD4 + CD25—populations) isolated from B6 mice were transformed with CTLA4-CD28 chimeric genes. 1 T-cell and used in combination therapy.
- CTLA4-CD28 transformation significantly increased IL-2 secretion in CD4 T-cells (see FIG. 5 (a))
- the present invention is directed to the therapeutic effect of gene-transformed T ⁇ cells in vivo. I knew if I needed -2. As expected, in vivo anti-IL-2 neutralizing antibody treatment resulted in almost no therapeutic effect of gene transformation (see FIG. 18). In conclusion, these results effectively inhibit tumors that have already grown significantly (pre-established) and immunogenicity by selective cell therapy with CTLA4-CD28 gene-transformed CD4 and CD8 T-cells. It has been shown that IL-2 contributes significantly to this therapeutic effect.
- Pmel-l EV is not transformed Pmel-1 T-cell
- CD4 EV is not transformed CD
- Pmel-1 CTC28 means F3 ⁇ 4el-1 T-cell transformed with CTLA4-CD28 chimeric gene
- CD4 CTC28 refers to CD4 T-cells transformed with CTLA4-CD28 chimeric gene.
- T-cell immunotherapy with T ⁇ cells transformed with the CTLA4-CD28 chimeric gene induced a large increase in antitumor effect in the combination therapy of CD4 and CD8 T-cells.
- the efficacy of anticancer T-cell immunotherapy can be greatly increased.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014538714A JP6074435B2 (ja) | 2011-10-26 | 2012-10-26 | 変異ctla4遺伝子移入t細胞及びこれを含む抗がん免疫治療用組成物 |
US14/354,562 US9688740B2 (en) | 2011-10-26 | 2012-10-26 | Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2011-0109729 | 2011-10-26 | ||
KR20110109729 | 2011-10-26 | ||
KR10-2012-0119603 | 2012-10-26 | ||
KR1020120119603A KR101471647B1 (ko) | 2011-10-26 | 2012-10-26 | 변이 ctla4 유전자 이입 t 세포 및 이를 포함하는 항암 면역치료용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013062365A2 true WO2013062365A2 (ko) | 2013-05-02 |
WO2013062365A3 WO2013062365A3 (ko) | 2013-06-20 |
Family
ID=48168732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2012/008878 WO2013062365A2 (ko) | 2011-10-26 | 2012-10-26 | 변이 ctla4 유전자 이입 t 세포 및 이를 포함하는 항암 면역치료용 조성물 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2013062365A2 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016203048A1 (en) * | 2015-06-19 | 2016-12-22 | Kobold Sebastian | Pd-1-cd28 fusion proteins and their use in medicine |
JP2021180686A (ja) * | 2014-04-23 | 2021-11-25 | ジュノー セラピューティクス インコーポレイテッド | 養子療法用の免疫細胞集団を単離、培養、および遺伝子操作するための方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200054178A (ko) | 2017-08-09 | 2020-05-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | 유전자 조작된 세포 조성물 및 관련 조성물의 제조 방법 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6090914A (en) * | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
-
2012
- 2012-10-26 WO PCT/KR2012/008878 patent/WO2013062365A2/ko active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6090914A (en) * | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
Non-Patent Citations (3)
Title |
---|
CARTELLIERI, M. ET AL.: 'Chimeric antigen receptor-engineered T cells for immunotherapy of cancer' JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY vol. 2010, 2010, page 13 * |
JENA, B. ET AL.: 'Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor' BLOOD vol. 116, no. 7, 03 May 2010, pages 1035 - 1044 * |
SHIN, J.H. ET AL.: 'Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models' BLOOD vol. 119, no. 24, 26 April 2012, pages 5678 - 87 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021180686A (ja) * | 2014-04-23 | 2021-11-25 | ジュノー セラピューティクス インコーポレイテッド | 養子療法用の免疫細胞集団を単離、培養、および遺伝子操作するための方法 |
WO2016203048A1 (en) * | 2015-06-19 | 2016-12-22 | Kobold Sebastian | Pd-1-cd28 fusion proteins and their use in medicine |
EP3909972A1 (en) * | 2015-06-19 | 2021-11-17 | Kobold, Sebastian | Pd1-cd28 fusion proteins and their use in medicine |
US11192935B2 (en) | 2015-06-19 | 2021-12-07 | Sebastian Kobold | PD-1-CD28 fusion proteins and their use in medicine |
Also Published As
Publication number | Publication date |
---|---|
WO2013062365A3 (ko) | 2013-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6074435B2 (ja) | 変異ctla4遺伝子移入t細胞及びこれを含む抗がん免疫治療用組成物 | |
AU2020203129B2 (en) | Enhancing the effect of CAR-engineered T cells by means of nucleic acid vaccination | |
JP7291396B2 (ja) | 融合タンパク質を用いたtcrの再プログラミングのための組成物及び方法 | |
ES2751945T3 (es) | Vector de expresión de un RAQ y células T que expresan un RAQ | |
JP7372728B2 (ja) | 改変t細胞に関する方法および組成物 | |
Hillerdal et al. | Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer | |
CN113286811A (zh) | 改善过继性细胞疗法的效力和安全性 | |
BR112020005938A2 (pt) | célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso | |
KR20190101979A (ko) | 합성 면역 수용체 및 이의 사용 방법 | |
WO2017219936A1 (zh) | 一种高效稳定表达激活型抗体的car-t细胞及其用途 | |
US20220033461A1 (en) | Antigen receptors and uses thereof | |
JP2021510540A (ja) | 修飾細胞の増幅およびその応用 | |
KR20150128997A (ko) | 면역치료용 조성물 및 방법 | |
WO2019136305A1 (en) | Cell-based and immune checkpoint inhibitor therapies combined with il-12 for treating cancer | |
KR20170093248A (ko) | 탄산무수화효소 ix 특이적 키메라 항원 수용체 및 이의 사용 방법 | |
US20220202862A1 (en) | Cd8 polypeptides, compositions, and methods of using thereof | |
JP7271037B2 (ja) | 免疫シナプスを安定化させるキメラ抗原受容体(car)t細胞 | |
Fujii et al. | Cancer immunotherapy using artificial adjuvant vector cells to deliver NY‐ESO‐1 antigen to dendritic cells in situ | |
JP2021509903A (ja) | 癌の長期car処置 | |
WO2013062365A2 (ko) | 변이 ctla4 유전자 이입 t 세포 및 이를 포함하는 항암 면역치료용 조성물 | |
WO2024060140A1 (zh) | EGFRvIII嵌合抗原受体及其用途 | |
RU2794945C2 (ru) | Антигенные рецепторы и их применение | |
US20220211831A1 (en) | Siglec-based chimeric polypeptides and uses thereof | |
Huang et al. | Immunotherapy for colorectal cancer | |
RU2792042C2 (ru) | Антигенные рецепторы и их применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12843439 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2014538714 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14354562 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12843439 Country of ref document: EP Kind code of ref document: A2 |